Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting
Retrieved on:
Tuesday, October 26, 2021
American College of Gastroenterology, Research, Endoscopy, Diagnosis, University, LGIB, Colorectal cancer, History, Security (finance), U.S. Securities and Exchange Commission, Patient, NASDAQ, Internal medicine, Private Securities Litigation Reform Act, UTMB, Biopsy, IBP, Colonoscopy, Motus, Forward-looking statement, Maintenance, Company, CRC, COVID-19, GI, Hepatology, Solution, American College, Howard Brody, Division, Intellectual property, EMR, Pleasure, GLOBE, Department, Colon, ACG, Medical imaging
We are excited to see the positive results of this real-world, independent study of the Pure-Vu System supporting both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting.
Key Points:
- We are excited to see the positive results of this real-world, independent study of the Pure-Vu System supporting both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting.
- Of the 40 procedures that we completed, the Pure-Vu was used as an adjunct to IBP to allow completion of procedure in 37 patients.
- Additionally, we successfully completed three procedures without any bowel preparation in patients with lower GI bleeds.
- In patients with IBP, the mean BBPS score improved from 3.1 (range: 0-6) to 8.5 (range 5-9) after intra-procedural cleansing.